Dr Reddy’s Acquired Mayne Pharma’s USA Prescription Portfolio
Dr. Reddy’s Laboratories (DRL) has agreed to buy Mayne Pharma Group’s US generic prescription product portfolio for $90 million up front and up to $15 million in contingent payments. The acquisition will add limited competition products to DRL’s US retail prescription pharmaceutical business. According to IQVIA, the total addressable market in the United States for […]
Continue Reading